Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BMS files IND, extends work with Five Prime
March 2018
SHARING OPTIONS:

SOUTH SAN FRANCISCO, Calif.—A milestone has been reached by Five Prime Therapeutics Inc. in its agreement with Bristol-Myers Squibb. The latter company submitted an IND application to the FDA for a therapeutic candidate developed under the immune checkpoint pathway discovery collaboration between Five Prime and BMS, triggering a $5-million milestone payment to Five Prime. The candidate in question is a fully human monoclonal antibody targeting TIM-3 (T cell immunoglobulin and mucin domain-3), an immune checkpoint receptor. Alongside this milestone, BMS has exercised its option to extend its collaboration with Five Prime, which will now last until March 2019, providing Five Prime with further funding for the expanded research term. The agreement grants BMS exclusive worldwide rights to develop and commercialize products against select protein targets in three checkpoint pathways.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.